Radiofrequency ablation of metastatic pheochromocytoma.
In the present report on the preliminary safety and effectiveness of radiofrequency (RF) ablation for pheochromocytoma metastases, seven metastases were treated in six patients (mean size, 3.4 cm; range, 2.2-6 cm). alpha- and beta-adrenergic and catecholamine synthesis inhibition and intraprocedural anesthesia monitoring were used. Safety was assessed by recording ablation-related complications. Complete ablation was defined as a lack of enhancement within the ablation zone on follow-up computed tomography. No serious adverse sequelae were observed. Complete ablation was achieved in six of seven metastases (mean follow-up, 12.3 months; range, 2.5-28 months). In conclusion, RF ablation may be safely performed for metastatic pheochromocytoma given careful attention to peri-procedural management.
Venkatesan
Aradhana M
AM
Center for Interventional Oncology, Department of Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, Maryland 20892, USA. venkatesana@cc.nih.gov
Locklin
Julia
J
Lai
Edwin W
EW
Adams
Karen T
KT
Fojo
Antonio Tito
AT
Pacak
Karel
K
Wood
Bradford J
BJ
D000310:Adrenal Gland Neoplasms / Q000601:surgery*; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000556:secondary* / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D010673:Pheochromocytoma / Q000556:secondary* / Q000601:surgery*; D016896:Treatment Outcome